ATE319460T1 - Onkolytisches vesicular stomatitis virus - Google Patents

Onkolytisches vesicular stomatitis virus

Info

Publication number
ATE319460T1
ATE319460T1 AT00965106T AT00965106T ATE319460T1 AT E319460 T1 ATE319460 T1 AT E319460T1 AT 00965106 T AT00965106 T AT 00965106T AT 00965106 T AT00965106 T AT 00965106T AT E319460 T1 ATE319460 T1 AT E319460T1
Authority
AT
Austria
Prior art keywords
virus
vesicular stomatitis
tumor cell
pkr
stomatitis virus
Prior art date
Application number
AT00965106T
Other languages
English (en)
Inventor
John Cameron Bell
Nahum Sonenberg
David Francis Stojdl
Earl Garnet Brown
Harold Lawrence Atkins
Ricardo Marcellus Marius
Brian Dennis Lichty
Shane Brendan Knowles
Original Assignee
Wellstat Biologics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Biologics Corp filed Critical Wellstat Biologics Corp
Application granted granted Critical
Publication of ATE319460T1 publication Critical patent/ATE319460T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/766—Rhabdovirus, e.g. vesicular stomatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20251—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20261—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
AT00965106T 1999-09-17 2000-09-18 Onkolytisches vesicular stomatitis virus ATE319460T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39787399A 1999-09-17 1999-09-17

Publications (1)

Publication Number Publication Date
ATE319460T1 true ATE319460T1 (de) 2006-03-15

Family

ID=23573018

Family Applications (2)

Application Number Title Priority Date Filing Date
AT05025974T ATE418341T1 (de) 1999-09-17 2000-09-18 Onkolytisches virus
AT00965106T ATE319460T1 (de) 1999-09-17 2000-09-18 Onkolytisches vesicular stomatitis virus

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT05025974T ATE418341T1 (de) 1999-09-17 2000-09-18 Onkolytisches virus

Country Status (13)

Country Link
EP (2) EP1218019B1 (de)
JP (1) JP5060694B2 (de)
CN (1) CN1289098C (de)
AT (2) ATE418341T1 (de)
AU (1) AU782402B2 (de)
CA (1) CA2386920C (de)
DE (2) DE60041210D1 (de)
ES (2) ES2260057T3 (de)
HK (2) HK1044708B (de)
IL (2) IL148621A0 (de)
MX (1) MXPA02002772A (de)
NZ (4) NZ534307A (de)
WO (1) WO2001019380A2 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
US7306902B2 (en) 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
US8491884B2 (en) 2000-05-03 2013-07-23 Oncolytics Biotech Inc. Virus clearance of neoplastic cells from mixed cellular compositions
IL153570A0 (en) 2000-06-26 2003-07-06 Wellstat Biologics Corp Purging of cells using viruses
US7122182B2 (en) 2001-05-11 2006-10-17 Wellstat Biologics Corporation Oncolytic virus therapy
US20030044386A1 (en) * 2001-07-11 2003-03-06 Barber Glen N. Recombinant VSV for the treatment of tumor cells
AU2008201293B2 (en) * 2001-07-11 2011-08-18 University Of Miami Recombinant VSV for the treatment of tumor cells
JP2004099584A (ja) 2002-05-02 2004-04-02 Keio Gijuku Ｈｓｖを用いた抗腫瘍剤
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
US7731974B2 (en) 2003-03-27 2010-06-08 Ottawa Hospital Research Institute Mutant vesicular stomatitis viruses and uses thereof
CN1788088B (zh) * 2003-03-27 2012-09-26 渥太华健康研究学会 突变的水泡性口炎病毒及其用途
WO2005117557A2 (en) 2004-06-01 2005-12-15 San Diego State University Foundation Expression system
CN101065144B (zh) * 2004-08-20 2012-06-13 溶瘤病毒有限公司 治疗血液癌症的方法和组合物
CA2577692C (en) 2004-08-20 2014-05-06 Viralytics Limited Methods and compositions for treatment of hematologic cancers
WO2007099401A2 (en) 2005-08-01 2007-09-07 University Technologies International, Inc. Oncolytic attenuated reoviruses for treatment of proliferative disorders
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
CA2921048C (en) 2006-09-15 2018-06-05 Ottawa Hospital Research Institute Oncolytic rhabdovirus
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
PE20091104A1 (es) * 2007-12-21 2009-07-18 Wyeth Corp Virus de la estomatitis vesicular atenuado modificado geneticamente, composiciones y metodos de uso del mismo
US10603351B2 (en) 2008-08-21 2020-03-31 Turnstone Limited Partnership Engineered synergistic oncolytic viral symbiosis
DE102008050860A1 (de) * 2008-10-08 2010-04-15 Dorothee Von Laer LCMV-GP-VSV-Pseudotypvektoren und tumorinfiltrierende Virenproduzentenzellen zur Therapie von Tumoren
ES2576036T3 (es) 2009-03-16 2016-07-05 Mcmaster University Métodos de vacunación
CN102858959B (zh) 2009-12-10 2016-02-24 渥太华医院研究院 溶瘤弹状病毒
US9428736B2 (en) 2010-09-02 2016-08-30 Mayo Foundation For Medical Education And Research Vesicular stomatitis viruses
US9951117B2 (en) 2010-09-02 2018-04-24 Mayo Foundation For Medical Education And Research Vesicular stomatitis viruses
CA2872045A1 (en) 2011-06-08 2012-12-13 Children's Hospital Of Eastern Ontario Research Institute Inc. Compositions and methods for glioblastoma treatment
ES2698076T3 (es) 2011-10-07 2019-01-30 Isd Immunotech Aps Identificación de los dominios inmunosupresores en las proteínas de fusión de los virus de ARN con envoltura
JP2016513115A (ja) 2013-02-21 2016-05-12 チルドレンズ ホスピタル オブ イースタン オンタリオ リサーチ インスティチュート インコーポレイテッド ワクチン組成物
PL2983706T3 (pl) 2013-04-10 2021-11-02 Isd Immunotech Aps Zastosowanie domen tłumiących układ immunologiczny jako leków
US10066214B2 (en) 2013-06-14 2018-09-04 Turnstone Limited Partnership Compositions and methods for enhancing virus replication
EP2826856B9 (de) * 2013-07-16 2016-05-04 Sia Latima Genetisch stabiles onkolytisches RNA-Virus, Verfahren zur Herstellung und Verwendung davon
EP3172562B1 (de) * 2014-07-21 2019-03-13 Novellusdx Ltd. Verfahren und systeme zur bestimmung des onkogenen index patientenspezifischer mutationen
CN105233285B (zh) * 2015-09-06 2018-10-12 广州威溶特医药科技有限公司 Epac直接或间接激动剂与溶瘤病毒的联合应用
US10610583B2 (en) 2017-08-31 2020-04-07 Regents Of The University Of Minnesota Methods and compositions for treating glioma and medulloblastoma brain tumors using the zika virus
CA3076094A1 (en) 2017-09-22 2019-03-28 Centre National De La Recherche Scientifique (Cnrs) Mutated glycoprotein of vesicular stomatitis virus
CN110499297B (zh) * 2019-08-29 2021-07-09 上海市公共卫生临床中心 一种新型溶瘤病毒及其制备方法和应用
WO2022033469A1 (zh) * 2020-08-14 2022-02-17 上海行深生物科技有限公司 重组溶瘤病毒及其构建方法和用途
EP4288140A1 (de) 2021-02-05 2023-12-13 Iovance Biotherapeutics, Inc. Adjuvante therapie für krebs

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1118403B (de) 1960-01-27 1961-11-30 Hoechst Ag Verfahren zur Gewinnung von antitumorwirksamen Sporen
GB1069144A (en) 1963-07-10 1967-05-17 Merck & Co Inc Method for the treatment of malignant tumors
US4806347A (en) 1985-12-11 1989-02-21 Schering Corporation Interferon combinations
PT713397E (pt) * 1992-03-24 2003-04-30 United Cancer Res Inst Vacina que contem virus vivos
GB9415320D0 (en) 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
US7153510B1 (en) * 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
ATE241994T1 (de) 1996-01-25 2003-06-15 Univ Glasgow Hsv-mutant-1716 zur behandlung von mesotheliomen
AU731663B2 (en) * 1997-07-11 2001-04-05 Yale University Rhabdoviruses with reengineered coats
ATE371372T1 (de) * 1997-10-09 2007-09-15 Wellstat Biologics Corp Behandlung von neoplasmen mit interferon- empfindlichen, klonalen viren
CA2316033A1 (en) * 1997-12-22 1999-07-01 The University Of Tennessee Research Corporation Recombinant rhabdovirus containing a heterologous fusion protein
AU3001799A (en) * 1998-03-12 1999-09-27 Trustees Of The University Of Pennsylvania, The Producer cells for replication selective viruses in the treatment of malignancy
IL140264A0 (en) * 1998-06-12 2002-02-10 Sinai School Medicine Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals
CA2370187C (en) * 1999-04-15 2011-08-02 Pro-Virus, Inc. Treatment of neoplasms with viruses

Also Published As

Publication number Publication date
NZ534307A (en) 2005-07-29
HK1092713A1 (en) 2007-02-16
EP1716858A3 (de) 2007-08-15
HK1044708A1 (en) 2002-11-01
ATE418341T1 (de) 2009-01-15
WO2001019380A2 (en) 2001-03-22
AU7588200A (en) 2001-04-17
CN1289098C (zh) 2006-12-13
DE60026554T2 (de) 2006-09-28
NZ523805A (en) 2004-09-24
AU782402B2 (en) 2005-07-28
CN1496268A (zh) 2004-05-12
ES2320239T3 (es) 2009-05-20
EP1218019B1 (de) 2006-03-08
CA2386920C (en) 2012-01-24
ES2260057T3 (es) 2006-11-01
EP1716858B9 (de) 2009-08-12
CA2386920A1 (en) 2001-03-22
WO2001019380A3 (en) 2001-11-22
IL148621A0 (en) 2002-09-12
NZ534306A (en) 2005-12-23
EP1218019A2 (de) 2002-07-03
NZ517573A (en) 2004-02-27
JP5060694B2 (ja) 2012-10-31
HK1044708B (zh) 2006-10-27
DE60041210D1 (de) 2009-02-05
JP2004525855A (ja) 2004-08-26
EP1716858A2 (de) 2006-11-02
EP1716858B1 (de) 2008-12-24
MXPA02002772A (es) 2004-04-02
DE60026554D1 (de) 2006-05-04
IL148621A (en) 2010-02-17

Similar Documents

Publication Publication Date Title
ATE418341T1 (de) Onkolytisches virus
DE60239394D1 (de) Onkolytische virustherapie
Haller et al. Host gene influences sensitivity to interferon action selectively for influenza virus
MY141594A (en) 3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES
MY133891A (en) Polyethylene glycol modified interferon therapy
ES2165269A1 (es) Derivados de alfa-cetoamidas.
DE69333321D1 (de) Verwendung eines Consensus-Interferons zur Reduzierung der Nebeneffekte in der Interferon Behandlung von viralen Hepatiten.
ATE451835T1 (de) Therapeutische verfahren und zusammensetzungen unter verwendung von viren der rekombinanten familie der paramyxoviridae
EA200100302A1 (ru) Способы и композиции для протективной и терапевтической генетической иммунизации
DE60136381D1 (de) Zusammensetzungen und verfahren zur modulierung von rsv-infektionen und -immunität
BR0109928A (pt) Uso de um herpes vìrus atenuado, e, método para estimular uma resposta imune em um indivìduo humano ou animal, ou para tratar ou prevenir uma infecção patogênica ou câncer em um indivìduo humano ou animal
WO2003017943A3 (en) Therapeutic compositions and methods for treating viral infection
WO2003015714A3 (en) Compositions and therapeutic methods for viral infection
ES2103811T3 (es) Terapia antiviral.
SG165996A1 (en) Combination therapies with l-fmau for the treatment of hepatitis b virus infection
WARFEL et al. Production and initial characterization of guinea pig interferon
DE69932741D1 (de) Verwendung von n-glycolneuraminsäure und deren derivaten zur herstellung eines medikaments zur behandlung von hiv-infektionen
ATE26267T1 (de) Pyrimidin-derivate, ausgestattet mit antiviraler wirkung.
Eylan et al. Resistance of aged cells to virus replication
DE69210737D1 (de) Verwendung von L-2-Oxothiazolidine-4-Carboxylate zur Herstellung eines Arzneimittels zur Behandlung von latenten HIV-Infektionen
ATE189604T1 (de) Extrakte von piliostigma thonningii, deren verwendung und diese enthaltende zubereitungen
TH23210EX (th) "อนุพันธุ์พลาวินใช้เป็นสารต่อต้านไวรัส"
DE69803052D1 (de) Therapeutischer viraler wirkstoff, welcher das fortschreiten von tumoren stoppt
DE69006187D1 (de) Verwendung von Chinolyl- und Isochinolyloxazol-2-onen zur Herstellung eines Arzneimittels zur Verhinderung der Ansteckungsfähigkeit von mit Glykoproteinen umhüllten Viren.
RU98109203A (ru) Способ лечения вирусного гепатита b у детей

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1218019

Country of ref document: EP